IL-21 and CD40L Synergistically Promote Plasma Cell Differentiation through Upregulation of Blimp-1 in Human B Cells

B. Belinda Ding, Enguang Bi, Hongshan Chen, J. Jessica Yu and B. Hilda Ye

*J Immunol* published online 16 January 2013
[http://www.jimmunol.org/content/early/2013/01/16/jimmunol.1201678](http://www.jimmunol.org/content/early/2013/01/16/jimmunol.1201678)

Supplementary Material

---

**Why The JI?**

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

---

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at: [http://jimmunol.org/subscription](http://jimmunol.org/subscription)

**Permissions**

Submit copyright permission requests at: [http://www.aai.org/About/Publications/JI/copyright.html](http://www.aai.org/About/Publications/JI/copyright.html)

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at: [http://jimmunol.org/alerts](http://jimmunol.org/alerts)
IL-21 and CD40L Synergistically Promote Plasma Cell Differentiation through Upregulation of Blimp-1 in Human B Cells

B. Belinda Ding,1 Enguang Bi,1 Hongshan Chen, J. Jessica Yu, and B. Hilda Ye

After undergoing Ig somatic hypermutation and Ag selection, germinal center (GC) B cells terminally differentiate into either memory or plasma cells (PCs). It is known that the CD40L and IL-21/STAT3 signaling pathways play critical roles in this process, yet it is unclear how the B cell transcription program interprets and integrates these two types of T cell–derived signals. In this study, we characterized the role of STAT3 in the GC-associated PC differentiation using purified human tonsillar GC B cells and a GC B cell-like cell line. When primary GC B cells were cultured under PC differentiation condition, STAT3 inhibition by AG490 prevented the transition from GC centrocytes to preplasmablast, suggesting that STAT3 is required for the initiation of PC development. In a GC B cell-like human B cell line, although IL-21 alone can induce low-level Blimp-1 expression, maximum Blimp-1 upregulation and optimal PC differentiation required both IL-21 and CD40L. CD40L, although having no effect on Blimp-1 as a single agent, greatly augmented the amplitude and duration of IL-21–triggered Jak-STAT3 signaling. In the human PRDM1 locus, CD40L treatment enhanced the ability of STAT3 to upregulate Blimp-1 by removing BCL6, a potent inhibitor of Blimp-1 expression, from a shared BCL6/STAT3 site in intron 3. Thus, IL-21 and CD40L collaborate through at least two distinct mechanisms to synergistically promote Blimp-1 activation and PC differentiation. The Journal of Immunology, 2013, 190: 000–000.

Received for publication June 18, 2012. Accepted for publication December 12, 2012.

This work was supported by National Institutes of Health Grant R01 CA85573 (to B.H.Y.) and a fellowship grant from the Lauri Strauss Leukemia Foundation (to B.B.D.).

Address correspondence and reprint requests to Dr. B. Hilda Ye, Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. E-mail address: hilda.ye@einstein.yu.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: CB, centroblast; CC, centrocyte; ChIP, chromatin immunoprecipitation; DLBCL, diffuse large B cell lymphoma; FDC, follicular dendritic cell; GC, germinal center; GCB, GC B cell-like; PB, plasmablast; PC, plasma cell; pre-PB, preplasmablast; qRT-PCR, quantitative RT-PCR; siRNA, small interfering RNA; Tfh, follicular T helper.

In vivo, PCs can be generated through the extracellular route, as well as the germinal center (GC) response (1). Although both pathways share a strict requirement for IRF4 and Blimp-1, the GC-associated PC differentiation has additional requirements and is subject to more elaborate control. Presumably, this is due to the fact that only the affinity matured GC B cells can give rise to long-lived PCs, as well as memory B cells (1, 2) so that, if dysregulated, these GC offspring will cause more damage to the organism compared with the short-lived extracellular Ab response (5). Three major differences exist between the two pathways of PC development. First, STAT3 is dispensable for T cell–independent, extracellular Ab response, but crucial for post-GC differentiation of IgG PCs (6). Nevertheless, the reason for this pathway-specific function of STAT3 is unknown; the specific stage of PC development that requires STAT3 function is also not defined. Second, initiation of PC differentiation within a GC B cell requires the downregulation of BCL6, a transcriptional repressor that inhibits the expression of three critical transcription factors for PC development, namely, STAT3, IRF4, and Blimp-1 (7–11). This BCL6-imposed barrier for PC differentiation is much lower for the extracellular pathways because naive B cells have very little BCL6 protein (12). Lastly, unique to the GC-associated PC development is the role played by follicular T helper (Tfh) cells, which regulate all aspects of the GC response (13). Recent multiphoton microscopy studies have suggested that GC B cells compete for limited Tfh help signals within the GC light zone (14, 15). A combination of this cognate B–T interaction and a direct contribution from the follicular dendritic cells (FDCs) (16) presumably provides the cellular basis for positive selection that licenses affinity matured GC B cells into the long-lived PC pools.

Tfh cells provide help to B cells through a variety of molecules that regulate GC initiation, maintenance, and post-GC B cell differentiation (17). In the light zone of established GCs, a major Tfh-derived help signal is delivered through CD40 ligation. Direct T–B contact in the GC light zone results in CD40L–CD40 engagement, which triggers NF-κB activation and IRF4 upregulation within the
B cell (18). IRF4, in turn, downregulates BCL6, thereby creating a permissive state for post-GC differentiation (18). Tfh cells also regulate Ig class switching and B cell maturation through several cytokines, including IFN-γ, IL-4, IL-10, IL-13, and IL-21. Recent studies have particularly focused on IL-21, a type I cytokine that has been recognized as the most potent driver of B cell terminal differentiation and acts directly on B cells to control GC formation and Ab production (19, 20). Of note, all three major cytokines involved in PC development, IL-21, IL-6, and IL-10, share the ability to activate STAT3. As pointed out earlier, although STAT3 is known to play a critical role in post-GC PC differentiation, the timing of STAT3 requirement in the PC development process has not been defined. It is also not clear whether and how STAT3 activation integrates other Tfh signals such as CD40L.

In this study, we used primary tonsillar GC B cells and a GC B cell-like (GCB) cell line system to characterize the signaling events leading to STAT3 activation and the subsequent changes in target gene expression and B cell phenotype. Our results confirm a number of previous reports but also provide novel insights regarding the timing of STAT3 requirement, the nature of cooperativity between CD40L and IL-21 signaling in GCB B cells, and the importance of competitive binding between BCL6 and STAT3 to the intron 3 site in the human PRDM1 locus. The cell line–based PC differentiation system we describe in this article is remarkably robust and amenable to detailed biochemical analysis and somatic cell genetics. It should serve as a valuable tool for future studies, in particular, with respect to the phenotypic transition from GCB cells to PC precursors.

**Materials and Methods**

**Purification of tonsillar centroblast B cells**

Human tonsils were obtained as discarded material from routine tonsillectomies with approval of the Institutional Review Boards of Albert Einstein College of Medicine and Montefiore Medical Center in accordance with Helsinki protocols. The FDC-like HC cells and the stable CD40L-CD8-transfected J558 cell line have been previously described (21, 22). GC centroblasts (CBs) were purified from freshly obtained tonsillar biopsies by one-step, magnetic cell separation based on CD77 as previously described (11). In brief, briefly miniced minced tonsillar tissue in ice-cold RPMI 1640 medium was passed through a 70-μm Nylon filter (BD Falcon). The cleared cell suspension was spun over Histopaque 1077 (Sigma-Aldrich) to obtain mononuclear cells. The recovered cells were washed twice with PBS before subsequent staining with three Abs. First, cells were suspended in 500 μl PBS + 4% FBS and incubated with anti-CD77 rat IgM Abs (clone 38-13, 15 μl per 1 × 10⁸ cells; Beckman Coulter). The stained cells were washed once with PBS and resuspended again in 500 μl PBS + 4% FBS, to which mouse anti-rat IgM Abs (cat. no. 553887; BD, Biosciences) was added (7 μl per 1 × 10⁸ cells). After incubation, the stained cells were washed, resuspended as before, and stained with rat anti-mouse IgG1 microbeads (cat. no. 130-047-101; 17 μl per 1 × 10⁸ cells; Miltenyi Biotec). All Ab binding steps were carried out on ice for 10–20 min. Finally, the stained cells were subjected to magnetic cell separation according to the manufacturer’s protocol. To isolate native B cells from tonsils, we used a two-step Ab staining procedure used to knockdown STAT3 in human B cell lines have been described previously (7). In brief, transient transfections were performed with the Nucleofector Kit T and program G1 (16) (Amaxa Biosystems). Ten micrograms of control or STAT3-directed siRNA oligos were used in each transfection of 5–10 million cells.

**Construction of Blimp-1 luciferase reporters and reporter assays in Ly7 cells**

A 1.71-kb genomic DNA fragment containing the intron 3 BCL6/STAT3 site was PCR amplified from the BAC clone RP11-458H5 using the following primer site–adapted PCR primers 5′-ACGCGTCGACGTCGGCA-TAGCGGCCGCGGAATCCTTGAATAAAACACTGGATTAGC-3′ (forward) and 5′-AGCCGTCCAGCTGCGCAATGCGCCGCGGAAGCAGAA-GAATGGAAGAATTTGA AGTTTGT-3′ (reverse). The PCR products were XhoI-digested and inserted into similarly digested Blimp-1 luciferase reporter containing the 1.67 kb 5′-promoter sequence (25). This resulted in inser-expressing 1.71 kb intron 3 downstream of the Blimp-1 promoter region. The composite BCL6/STAT3 site, TCTCTGGA, was subsequently mutated to TCTCTGGA by site-directed mutagenesis using the QuikChange II kit (Stratagene). All constructs were sequence verified. For reporter assays, 6 million Ly7 cells were transfected using the Nucleofector Kit T and program G16 with 1 pmol of the Luciferase reporters (4.5–5.7 μg) plus 3 μg of a β-galactosidase control plasmid. After overnight incubation, transfected cells were either left untreated or subject to IL-21/CD40L costimulation for 44 h. Luciferase activities were measured with a luciferase assay kit (Promega). The intron 3 luciferase activity was normalized to the β-galactosidase activity, and values are shown as fold change.

**Quantitative RT-PCR and Western blotting**

Western blotting and quantitative RT-PCR (qRT-PCR) were performed using standard techniques as previously described (26). Primers used for qRT-PCR are listed in Supplemental Table I. Primary Abs used for Western blot analysis were purchased from Santa Cruz Biotechnology for BCL6 (sc-858), Blimp-1 (sc-47732), IRF4 (sc-6059), Pax5 (sc-1974), STAT3 (sc-8019 and sc-482), and GAPDH (sc-25778); from Cell Signaling Technology for Jak3 (sc-37755), STAT1 (sc-9172), PY-Jak1 (sc-3331), STAT1 (sc-9171), PY-STAT3 (sc-9131), and PS-STAT3 (sc-9123); and from BD Pharmingen for IL-21R (560264); and from Invitrogen Life Science for PY-Jak2 (44-426G), and from Calbiochem for MTA3 (IM1012). Mum1 mAb (IgG1 clone 2H9) was obtained from Dr. Falini at University of Perugia, Italy.

**ELISA**

Levels of secreted Abs in the culture supernatants were measured using Human IgM and IgG ELISA Quantitation Kits (cat. no. E80-100 and E80-104; Bethyl Laboratories). Serial dilutions and standard curves were performed to calculate Ab concentrations based on 1/2 V₅₀ using GraphPad Prism.
Quantitative chromatin immunoprecipitation

We used a previously described protocol for locus-specific chromatin immunoprecipitation (ChIP) in lymphoma cell lines and quantitative measurement of enriched DNA material (26). The same BCL6 and STAT3 polyclonal Abs used for Western blot were used in these experiments. The primers used for qPCR are listed in Supplemental Table I.

Results

Jak/STAT activity is required for the centrocyte to pre-PB transition in an in vitro PC differentiation system

To study the timing and consequence of STAT3 activation with respect to PC differentiation stages, we turned to a previously described in vitro differentiation system for tonsil GC B cells (27–29). Specifically, GC CBs were purified from tonsils using CD77-based magnetic beads enrichment and subsequently cultured on the HK feeder cell line in the presence of soluble CD40L, IL-2, and IL-4. As shown in Fig. 1, robust PC differentiation was induced in 10–12 d based on gradual changes in surface phenotype, transcription factor expression, and Ig secretion capability.

Specifically, freshly isolated GC CBs had high levels of BCL6 and Pax5, both of which ceased expression rapidly in the differentiation medium and were replaced by transcription factors associated with PC differentiation after a week, namely, Tyr705 phosphorylated STAT3 (PY-STAT3), Blimp-1, and IRF4 (Fig. 1B). Expression of IRF4 was also examined by the Mumi1 Ab, which recognizes a conformational epitope preferentially expressed by nuclear localized IRF4 (30). After 1 wk, Ig secretion started to increase steadily, reaching 100 μg IgM per 10⁶ cells/ml on day 11 (Fig. 1C). Although the trend for IgG Ab was the same, the levels were ∼1000 times lower, indicating inefficient class switching in vitro. We also examined B cell phenotype changes based on surface marker expression.

As previously reported, freshly purified human GC CBs were CD20⁺CD38⁺. During the next 10 d, two other phenotypes gradually emerged under our culture condition: CD20⁺CD38⁻ and CD20⁻CD38⁻, which are referred to as centrocytes (CCs) and PBs, respectively, based on previous reports (27–29) (Fig. 1A). Although culture cocktails that include CD40L are reported to produce CD20⁺CD38⁻ memory B cells, we rarely detected these cells possibly because of suboptimal CD40L stimulation in our cultures. Interestingly, in addition to the CC and PB subsets, we also observed a CD20⁺CD38⁻ population that appears to represent an intermediate phenotype. This population was most prominent on day 7 as the CC fraction started to decrease, and began to contract on day 10 when the PB subset started to dominate the culture (Fig. 1A).

To examine the role of Jak/STAT signaling in this system, we added the Jak inhibitor, AG490, to parallel cultures. In some experiments, the effect of IL-21 was also tested. In the presence of AG490, the CB-to-CC transition was not affected, an observation consistent with our previous report that all tonsillar CBs are STAT3⁻ (7). However, AG490 substantially blocked the transition from CC to the CD20⁺CD38⁻ population on day 7, leading to a drastic reduction of the CD20⁺CD38⁻ PBs in later stages of the culture, such as shown on day 10. Consistent with the PC-promoting activity of the IL-21/Jak/STAT3 axis, Ig secretion was also reduced by AG490 but notably enhanced by IL-21 (Fig. 1C). This AG490 effect not only confirms our interpretation that the CD20⁺CD38⁻ population is the predecessor to the CD20⁺CD38⁻ PBs, it also suggests that Jak/STAT activity is required for CC to acquire this next, more mature phenotype (CD20⁺CD38⁻). We also looked for gene expression changes associated with the transition from CD20⁺CD38⁻ to CD20⁺CD38⁻ phenotype. qRT-PCR experiments revealed that between days 6 and 8 when the CD20⁺CD38⁻ fraction started to appear, there was an abrupt increase in both Jak3 and IRF4 mRNA; more importantly, such increase was delayed and reduced in AG490-treated cultures (Fig. 1D). Of note, Jak3 is a well-known STAT3 target gene (Ref. 31 and data not shown), whereas upregulation of IRF4 was previously reported to coincide with the appearance of pre-PB in mouse B cells (2).

A cell line–based system to study post-GC PC differentiation

Although our experiments with purified human GC B cells were very informative, we needed an experimental system that was more amenable to molecular and biochemical analyses. To this end, we screened a panel of GCB-DLBCL cell lines for their ability to undergo PC differentiation under costimulation by IL-21 and cell membrane-bound CD40L. Among the three responsive cell lines identified, including Ly7, Ly8, and SuDHL6, Ly7 was the most responsive and was used for the rest of our study. Unstimulated Ly7 cells and Ly7 cells exposed to the control 3T3 feeder for <1 wk displayed a CD20⁺CD38⁺ (CB/CC) phenotype (Fig. 2A and data not shown). This phenotype was not altered when Ly7 cells were subjected to either IL-21 or 3T3-CD40L single treatment for 1 wk. In contrast, in the IL-21/CD40L costimulation culture, only 19% of the cells remained CD20⁺CD38⁺, whereas 57% adopted a CD20⁺CD38⁻ phenotype (pre-PB like) and 23% were CD20⁺CD38⁻ (PB-like; Fig. 2A, top panels). After 2-wk stimulation, 21% of the cells exposed to control 3T3 feeder cells and nearly all the cells stimulated with 3T3-CD40L had become CD20⁺CD38⁻ (pre-PB). However, CD20⁺CD38⁻ cells (PBs) were only seen in the IL-21 culture and more prominently detected under IL-21/CD40L costimulation condition (Fig. 2A, bottom panels). The CD20⁺CD38⁻ PBs were also positive for CD27 but negative for Syndecan/CD138 (data not shown). Consistent with the notion that the CD20⁺CD38⁻ subset has the pre-PB phenotype (limited Ig secretion capacity), whereas the CD20⁺CD38⁻ cells possess PB-like features (better Ig producers), ELISA revealed that IL-21 alone had a modest stimulatory effect on IgM and IgG production, which was most obvious after 2 wk of treatment. Cells treated with CD40L alone also produced low levels of IgM and IgG. The highest levels of IgM and IgG were detected with IL-21/CD40L costimulation, reaching ~12 μg/ml and 170 ng/ml, respectively, after 2 wk of culture. This result indicates that the Ly7 cell line supports the synergistic effect of IL-21 and CD40L previously reported in primary mouse and human B cells. It is of note under the costimulation condition, the gradual increase in IgG titers closely paralleled that of IgM, suggesting a lack of progressive class switching. Two other GCB-DLBCL cell lines, Ly8 and SuDHL6, also responded to the costimulation with similar but milder changes in cell-surface CD20/CD38 expression and Ig secretion (data not shown).

IL-21 and CD40L synergistically induce Blimp-1 expression in a STAT3-dependent manner

Numerous in vivo studies have shown that nearly all factors important for the early stage of PC differentiation exert their effect through activation and/or maintenance of Blimp-1, the PC master regulator encoded by the PRDM1 gene. We therefore sought to compare IL-21 and CD40L in their abilities to activate Blimp-1 in a STAT3-responsive and was used for the rest of our study. Unstimulated Ly7 cells and Ly7 cells exposed to the control 3T3 feeder for <1 wk displayed a CD20⁺CD38⁺ (CB/CC) phenotype (Fig. 2A and data not shown). This phenotype was not altered when Ly7 cells were subjected to either IL-21 or 3T3-CD40L single treatment for 1 wk. In contrast, in the IL-21/CD40L costimulation culture, only 19% of the cells remained CD20⁺CD38⁺, whereas 57% adopted a CD20⁺CD38⁻ phenotype (pre-PB like) and 23% were CD20⁺CD38⁻ (PB-like; Fig. 2A, top panels). After 2-wk stimulation, 21% of the cells exposed to control 3T3 feeder cells and nearly all the cells stimulated with 3T3-CD40L had become CD20⁺CD38⁻ (pre-PB). However, CD20⁺CD38⁻ cells (PBs) were only seen in the IL-21 culture and more prominently detected under IL-21/CD40L costimulation condition (Fig. 2A, bottom panels). The CD20⁺CD38⁻ PBs were also positive for CD27 but negative for Syndecan/CD138 (data not shown). Consistent with the notion that the CD20⁺CD38⁻ subset has the pre-PB phenotype (limited Ig secretion capacity), whereas the CD20⁺CD38⁻ cells possess PB-like features (better Ig producers), ELISA revealed that IL-21 alone had a modest stimulatory effect on IgM and IgG production, which was most obvious after 2 wk of treatment. Cells treated with CD40L alone also produced low levels of IgM and IgG. The highest levels of IgM and IgG were detected with IL-21/CD40L costimulation, reaching ~12 μg/ml and 170 ng/ml, respectively, after 2 wk of culture. This result indicates that the Ly7 cell line supports the synergistic effect of IL-21 and CD40L previously reported in primary mouse and human B cells. It is of note under the costimulation condition, the gradual increase in IgG titers closely paralleled that of IgM, suggesting a lack of progressive class switching. Two other GCB-DLBCL cell lines, Ly8 and SuDHL6, also responded to the costimulation with similar but milder changes in cell-surface CD20/CD38 expression and Ig secretion (data not shown).

IL-21 and CD40L synergistically induce Blimp-1 expression in a STAT3-dependent manner

Numerous in vivo studies have shown that nearly all factors important for the early stage of PC differentiation exert their effect through activation and/or maintenance of Blimp-1, the PC master regulator encoded by the PRDM1 gene. We therefore sought to compare IL-21 and CD40L in their abilities to activate Blimp-1 in differentiating Ly7 cells. Unstimulated Ly7 cells displayed a typical GC B cell phenotype: BCL6, MTA3, and Pax5 high, STAT3 and IRF4 low, PY-STAT3 and Blimp-1 negative (Fig. 3A, lane 1). IL-21 alone activated PY-STAT1/3, which was accompanied by the appearance of PY-Jak1 and elevated total Jak3 (lane 2), but not PY-STAT5/6 (data not shown). Interestingly, IL-21 as a single agent also upregulated IRF4 moderately and weakly induced Blimp-1 (Fig. 3A, comparing lane 2 with lane 1 and lane 5 with
lane 3; a more typical Blimp-1 response to IL-21 is shown in Fig. 3B, lane 2 compared with lane 1). Although results shown in Fig. 1A are 46 h after stimulation, IL-21–triggered increase in Jak3, STAT3, IRF4, and Blimp-1 was detected as early as 24 h (Supplemental Fig. 1). CD40L alone had no effect on Blimp-1, although it increased IRF4 and Jak3, whereas reducing the expression of BCL6 and PY-Jak2 (Fig. 3A, comparing lane 4 with lane 3). Most importantly, we observed a substantial synergism between IL-21 and CD40L in upregulating Blimp-1 (comparing lane 6 with lanes 4 and 5). Similar cooperative effects were also observed for PY-Jak1, PY-STAT1/3, and total STAT3. The influence from IL-21 and CD40L on IRF4 and Jak3 appeared to be additive. Pax5 and MTA3 levels remained fairly constant through all treatments with the exception of a mild MTA3 reduction under the costimulation condition (Fig. 3A, lane 6).

Because both STAT1 and STAT3 were activated after IL-21 stimulation, we used RNA interference to examine the requirement for STAT3 in this system. As shown in Fig. 3B, siRNA-mediated STAT3 knockdown (Fig. 3B, bottom panel) markedly reduced the increase in PY-STAT3, IRF4, and most importantly, Blimp-1 in response to IL-21, as well as to the IL-21/CD40L costimulation. This result is consistent with a recent human study showing that STAT3, but not STAT1, is required for long-lived Ab response and IL-21–induced Ig secretion in vitro (32). Both Jak1 and Jak3 are known to be critical to the cellular response to IL-21 (33, 34). Using siRNA-mediated Jak3 knockdown, we confirmed that much of the IL-21–associated gene expression changes were also Jak3 dependent (data not shown). In addition to confirming a critical role of STAT3 and Jak3 in IL-21–driven PC differentiation, our results also show that in Ly7 cells, the wiring and property of the IL-21R/Jak/STAT pathway are the same as in primary human B cells.

**CD40L costimulation altered the dynamics of IL-21R/Jak/STAT3 signaling**

The synergism between IL-21 and CD40L in promoting PC development and Ab secretion has been previously reported (35, 36). However, the underlying mechanism has not been examined in great detail. Given the central role of Jak/STAT3 signaling in our experimental system, we analyzed the influence of CD40L/CD40
binding on IL-21R signaling. In a simple setting, Jak/STAT signaling downstream of cytokine receptors features a rapid activation/deactivation cycle (37). This phenomenon was also observed in IL-21–treated Ly7 cells that were pre-exposed to control 3T3 feeder cells. Specifically, the PY-STAT3 signal rose quickly after IL-21 stimulation and plateaued around 30 min to 1 h; by 3 h, it was already reduced to about half of its peak level (Fig. 4A, 4B). In comparison, CD40L pretreatment increased the amplitude of PY-STAT3 response by ∼85%. More importantly, the strength of the PY-STAT3 signal remained at near peak level at 3 h, indicating a much sustained response (Fig. 4A, right panel, Fig. 4B). We also examined changes in phospho-Ser727 STAT3 and observed a similar, yet milder trend compared with PY-STAT3 (Fig. 4A).

We then examined the effect of CD40L pretreatment on the key components of the IL-21R signaling complex during the first 3 h of IL-21 stimulation. Although CD40L did not change the total IL-21R protein based on Western blot analysis (Fig. 4A), flow cytometry revealed that the surface expression of IL-21R was much higher in CD40L pretreated cells before IL-21 exposure (Fig. 4C, 4D, MFI 20.2 versus 11.9). Interestingly, IL-21 treatment caused a rapid IL-21R downmodulation so that by 1 h, <40% of the initial level remained on the cell surface, and this amount persisted until at least 3 h (Fig. 4C and data not shown). The same residual amount of IL-21R was detected when IL-21 concentration varied between 20 and 100 ng/ml and irrespective of CD40L pretreatment (Fig. 4D). Because the CD40L-pretreated cells had higher levels of surface IL-21R before IL-21 exposure but retained the same amount of IL-21–resistant receptors on the cell surface, enhanced Jak/STAT signaling in these cells must originate from the internalized IL-21/IL-21R/Jak/STAT complexes within the endocytic compartment.

**Collaboration of signals transduced from CD40 and IL-21R on the PRDM1 locus**

Because Blimp-1 upregulation epitomized the collaborative effect between CD40L and IL-21, we studied transcription regulation of the PRDM1 locus. By qRT-PCR analysis, we first confirmed that costimulation with IL-21 and CD40L had the same synergistic effect on Blimp-1 mRNA as observed on its protein (Fig. 5A). Similar synergistic effects were also detected for Jak3 and STAT3 mRNA (Supplemental Fig. 2). Using the MatInspector program (38), we identified three candidate STAT3 binding sites in the 5′ regulatory region of the human PRDM1 locus (Fig. 5B). Of note, because sites B and C are only 147 bp apart, binding to them could not be resolved using PCR-based ChIP analysis. Although all three sites can be recognized by STAT3 in in vitro binding assays (data not shown), activated STAT3 was recruited only to site B/C, but not A, in Ly7 cells treated with either IL-21 or IL-21 plus CD40L (Fig. 5C, top panel, and data not shown). Interestingly, IL-21/CD40L costimulation increased STAT3 occupancy at site B/C by only 30% relative to IL-21 single treatment. Considering the pronounced synergistic effect of IL-21 plus CD40L on Blimp1 mRNA, we reasoned that additional regulatory element(s) must exist in this locus that are more sensitive to the concurrent signaling through IL-21R and CD40. To this end, we examined the high-affinity BCL6 binding site in the intron 3 because it is the
after IL-21 stimulation, although the total amount of BCL6 in the exclusively occupied by BCL6 (Fig. 5C, bottom panel). Consistent with our observation that CD40L/CD40 engagement did not activate STAT3, CD40L pretreatment did not induce STAT3 binding to any of the STAT3 sites tested; however, it reduced BCL6 binding to the intron 3 site by ∼30% (Fig. 5C, bottom panel); this corresponded to a 50% reduction in cellular BCL6 levels (Supplemental Fig. 3B). Presumably, this CD40L effect on BCL6 was the result of NF-κB activation and subsequent IRF4 upregulation (18). Under the co-stimulation condition, although the total BCL6 protein was not further reduced, BCL6 binding to the intron 3 site was decreased by another 30%; at the same time, STAT3 binding to this site was more than doubled relative to the IL-21 treatment alone (Fig. 5C, middle panel). We then turned to transient transfection-based Luciferase reporter assays to address the role of the intron 3 BCL6/STAT3 site in a functional setting. As shown in Fig. 5D, only the intron 3–containing constructs but not the promoter only reporter responded to IL-21/CD40L costimulation. In addition, in unstimulated Ly7 cells, the reporter containing the wild type intron 3 sequence had a significantly lower Luciferase reading compared with the promoter only reporter, and this difference disappeared when the BCL6/STAT3 composite site was mutated (reporter I3-Mut in Fig. 5D). This result is consistent with our chromatin IP analysis showing BCL6 occupancy of this site in unstimulated Ly7 cells (Fig. 5C). Although the activity of wild type intron 3 sequence more than doubled in response to IL-21/CD40L costimulation, a 40% increase was also observed with the I3-Mut reporter. This is likely due to the remaining STAT-like sites in the 1.7-kb intron 3 sequence. In summary, these data revealed that BCL6 and STAT3 bind in a competitive fashion to the shared PRDM1 intron 3 site that plays a key role in Blimp-1 upregulation. In addition, the synergistic action of CD40L and IL-21 on Blimp-1 expression is recapitulated by the dynamics of BCL6 and STAT3 recruitment to this intron 3 motif.

Discussion

Although STAT3 has emerged as a key regulator of GC-associated PC development, upstream signaling events leading to its activation and its downstream transcription and cellular effects are incompletely characterized. In this study of human GC B cells, we showed that STAT3 activation is required for activated CCs to acquire the CD20+CD38− pre-PB phenotype. In addition, we also demonstrate for the first time, to our knowledge, that concurrent CD40L, stimulation potentiates IL-21–driven Blimp-1 upregulation and PC differentiation by altering IL-21/Jak/STAT3 signaling dynamics and by displacing BCL6 from the shared BCL6/STAT3 site in intron 3 of the PRDM1 locus (summarized in Fig. 5E).

Studies using the Blimp-1–GFP reporter mice showed that PC differentiation begins with the appearance of pre-PBs that are Pax5+IRF4+Blimp-1+/−CD138− (2, 3). Yet, extracellular signals and key transcriptional changes that drive this GC-to-pre-PB transition are not fully understood. We previously reported that in tonsillar GC B cells, the decline in BCL6 is associated with STAT3 activation and upregulation (18). Under the co-stimulation condition, although the total BCL6 protein was not further reduced, BCL6 binding to the intron 3 site was decreased by another 30%; at the same time, STAT3 binding to this site was more than doubled relative to the IL-21 treatment alone (Fig. 5C, middle panel). We then turned to transient transfection-based Luciferase reporter assays to address the role of the intron 3 BCL6/STAT3 site in a functional setting. As shown in Fig. 5D, only the intron 3–containing constructs but not the promoter only reporter responded to IL-21/CD40L costimulation. In addition, in unstimulated Ly7 cells, the reporter containing the wild type intron 3 sequence had a significantly lower Luciferase reading compared with the promoter only reporter, and this difference disappeared when the BCL6/STAT3 composite site was mutated (reporter I3-Mut in Fig. 5D). This result is consistent with our chromatin IP analysis showing BCL6 occupancy of this site in unstimulated Ly7 cells (Fig. 5C). Although the activity of wild type intron 3 sequence more than doubled in response to IL-21/CD40L costimulation, a 40% increase was also observed with the I3-Mut reporter. This is likely due to the remaining STAT-like sites in the 1.7-kb intron 3 sequence. In summary, these data revealed that BCL6 and STAT3 bind in a competitive fashion to the shared PRDM1 intron 3 site that plays a key role in Blimp-1 upregulation. In addition, the synergistic action of CD40L and IL-21 on Blimp-1 expression is recapitulated by the dynamics of BCL6 and STAT3 recruitment to this intron 3 motif.

Discussion

Although STAT3 has emerged as a key regulator of GC-associated PC development, upstream signaling events leading to its activation and its downstream transcription and cellular effects are incompletely characterized. In this study of human GC B cells, we showed that STAT3 activation is required for activated CCs to acquire the CD20+CD38− pre-PB phenotype. In addition, we also demonstrate for the first time, to our knowledge, that concurrent CD40L, stimulation potentiates IL-21–driven Blimp-1 upregulation and PC differentiation by altering IL-21/Jak/STAT3 signaling dynamics and by displacing BCL6 from the shared BCL6/STAT3 site in intron 3 of the PRDM1 locus (summarized in Fig. 5E).

Studies using the Blimp-1–GFP reporter mice showed that PC differentiation begins with the appearance of pre-PBs that are Pax5+IRF4+Blimp-1+/−CD138− (2, 3). Yet, extracellular signals and key transcriptional changes that drive this GC-to-pre-PB transition are not fully understood. We previously reported that in tonsillar GC B cells, the decline in BCL6 is associated with STAT3 activation and upregulation (18). Under the co-stimulation condition, although the total BCL6 protein was not further reduced, BCL6 binding to the intron 3 site was decreased by another 30%; at the same time, STAT3 binding to this site was more than doubled relative to the IL-21 treatment alone (Fig. 5C, middle panel). We then turned to transient transfection-based Luciferase reporter assays to address the role of the intron 3 BCL6/STAT3 site in a functional setting. As shown in Fig. 5D, only the intron 3–containing constructs but not the promoter only reporter responded to IL-21/CD40L costimulation. In addition, in unstimulated Ly7 cells, the reporter containing the wild type intron 3 sequence had a significantly lower Luciferase reading compared with the promoter only reporter, and this difference disappeared when the BCL6/STAT3 composite site was mutated (reporter I3-Mut in Fig. 5D). This result is consistent with our chromatin IP analysis showing BCL6 occupancy of this site in unstimulated Ly7 cells (Fig. 5C). Although the activity of wild type intron 3 sequence more than doubled in response to IL-21/CD40L costimulation, a 40% increase was also observed with the I3-Mut reporter. This is likely due to the remaining STAT-like sites in the 1.7-kb intron 3 sequence. In summary, these data revealed that BCL6 and STAT3 bind in a competitive fashion to the shared PRDM1 intron 3 site that plays a key role in Blimp-1 upregulation. In addition, the synergistic action of CD40L and IL-21 on Blimp-1 expression is recapitulated by the dynamics of BCL6 and STAT3 recruitment to this intron 3 motif.

Discussion

Although STAT3 has emerged as a key regulator of GC-associated PC development, upstream signaling events leading to its activation and its downstream transcription and cellular effects are incompletely characterized. In this study of human GC B cells, we showed that STAT3 activation is required for activated CCs to acquire the CD20+CD38− pre-PB phenotype. In addition, we also demonstrate for the first time, to our knowledge, that concurrent CD40L, stimulation potentiates IL-21–driven Blimp-1 upregulation and PC differentiation by altering IL-21/Jak/STAT3 signaling dynamics and by displacing BCL6 from the shared BCL6/STAT3 site in intron 3 of the PRDM1 locus (summarized in Fig. 5E).

Studies using the Blimp-1–GFP reporter mice showed that PC differentiation begins with the appearance of pre-PBs that are Pax5+IRF4+Blimp-1+/−CD138− (2, 3). Yet, extracellular signals and key transcriptional changes that drive this GC-to-pre-PB transition are not fully understood. We previously reported that in tonsillar GC B cells, the decline in BCL6 is associated with STAT3 activation and upregulation, and that this transient state of STAT3 activity precedes high-level Blimp-1 expression (7). Furthermore, B cells with activated STAT3 are only found in the apical light zone, a location rich in FDC and Tfh. From a developmental perspective, these PY-STAT3+ CCs should correspond to the pre-PB stage. This notion is supported by three lines of evidence. First, STAT3 provides an activating signal for both IRF4 and Blimp-1 upregulation (Figs. 1D, 3B). Second, persistent Jak/STAT activity is required for the appearance of the CD20+CD38− cells and the CD20+CD38+ PB fractions (Fig. 1A), and the ultimate
is a direct target gene of BCL6 (7), this model also implicates
Blimp-1 and high-level Blimp-1 expression (Fig. 5E). Given that STAT3
thereby enabling maximum STAT3 recruitment to the
IRF4 promoter region in Ly7 cells treated with IL-21
and CD40L, BLIMP-1 expression was never detected
in Ly7 cells (Figs. 1D, 3B). In addition, STAT3 was inducibly re-
tered to the IRF4 promoter region in Ly7 cells treated with IL-
21. Furthermore, STAT3 can upregulate IRF4 promoter activity
in reporter assays (not shown). All of these observations suggest that
IRF4 is a direct target gene of STAT3. In a previous study, forced
overexpression of IRF4 was found to upregulate BLIMP-1 mRNA
in Ly7 cells (40). In our experiments, however, STAT3 clearly
plays a much more important role than IRF4 in driving BLIMP-1
upregulation. This is because IL-21 alone can induce low levels
of BLIMP-1 despite the paradoxical elevation of BCL6 protein, the
inhibitor of BLIMP-1 (Fig. 3A). The IRF4 component of the IL-21
response is unlikely to be the major driver because in cells ex-
posed to CD40L alone, BLIMP-1 expression was never detected
despite a similar IRF4 increase and the concurrent disappearance
of BCL6, a condition that should favor Blimp-1 activation (Fig.
5E). Given that STAT3 is a direct target gene of BCL6 (7), this model also implicates
STAT3, as opposed to IRF4 or Blimp-1, as the most proximal target
of BCL6 in its ability to inhibit PC differentiation.

Our results in this study also have notable implications for how
the PC differentiation program might integrate different inputs in
the GC microenvironment. FDCs and their associated complement
and FeRs have long been recognized as important factors for
affinity-based selection of long-lived PCs (16). The central role
played by Tfh cells, however, was only recently proposed. Multi-
photon microscopy studies showed that GC B cells loaded with
FDC-derived Ags compete for the limited number of Tfh cells in
the GC light zone (14, 15). Such observations predict that the BCR
affinity-based access to FDC-associated Ag is translated into the
amount of MHC-presented peptides to Tfh cells, and hence the
difference in receiving proliferation/survival signals (5). A major
finding of our study is that optimal Jak/STAT3 signaling and
BLIMP-1 upregulation requires concurrent CD40L/CD40 interac-
tion. Incorporating our results into the earlier model, we would
like to further propose that one type of critical T cell help deliv-
ered after T–B interaction is via the membrane-bound CD40L,
which, in addition to promoting proliferation/survival, greatly
augments the cell signaling and differentiation potential of IL-21,
thus facilitating the GC-to-PC phenotypic transition. This key
requirement for direct T–B interaction also safeguards against
selection of low-affinity, bystander B cells that may be exposed to
IL-21 signal as they traverse the vicinity of Tfh cells.

Findings presented in this study also revealed novel insights into
the synergy between IL-21 and CD40L. Although we observed a
steady increase in IL-21R mRNA in Ly7 cells treated with IL-21
and CD40L (Supplemental Fig. 2), no apparent change was de-
tected at the protein level after 16–24 h (Fig. 4A). Nevertheless,
CD40L, priming greatly enhanced the expression of IL-21R on the
cell surface (Fig. 4C), which may explain the heightened initial
IL-21 response. The much prolonged duration of Jak/STAT3 sig-
naling, however, is unlikely to be caused by the elevated surface
IL-21R level per se. A more attractive possibility is that CD40L
priming triggered downregulation or physical seclusion of mole-
cules that are normally responsible for the rapid inactivating phase
of Jak/STAT signaling, for example, protein tyrosine phospha-
tases and the SOCS proteins. In addition to this cell membrane-
proximal effect, signals transduced from CD40 and IL-21R also
cooperated at the chromatin level to regulate Blimp-1 expression.

FIGURE 4. Engagement of the CD40 receptor potentiates Jak/STAT3 signaling
by upregulating surface IL-21R expression. Ly7 cells were cultured for 16 h on
either the control 3T3 (3T3-ctrl) or 3T3-CD40L feeder cells before IL-21 stimu-
lation. (A) Whole-cell lysates were prepared at the indicated time points during
IL-21 treatment and analyzed by Western blot for the indicated protein markers.
(B) Normalized intensity of PY-STAT3 bands was plotted against IL-21 treat-
ment time. The graph shows the mean ± SD of two independent experiments. (C
and D) Aliquots of cells that were either untreated or exposed to varying concen-
trations of IL-21 for 1 h were analyzed for surface IL-21R expression. FACS
profiles for untreated cells and those treated with 100 ng/ml IL-21 are shown
in (C). Mean fluorescence intensity (MFI) values for all samples are listed in (D).
In this case, the key is competitive binding of BCL6 and STAT3 to the shared intron 3 site in the PRDM1 locus. Specifically, although CD40L/CD40 did not activate Blimp-1 transcription, it primed the locus for activation by downregulating BCL6 (Fig. 5C, Supple-mental Fig. 3B). In comparison, IL-21 as a single agent activated STAT3 but also increased BCL6, thus sending conflicting signals to the PRDM1 locus (Fig. 3A) (41). Synergy was achieved when STAT3 was optimally loaded to both the 5’ regulatory sites and the intron 3 site under costimulation by both IL-21 and CD40L (Fig. 5E).

Transcriptional regulation of Blimp-1 has been intensely inves-tigated, with the majority of the published studies focusing on the murine Prdm1 gene and the 3’ regulatory sequence of this locus.
In our study, we focused on the shared BCL6/STAT3 site in the human PRDM1 intron 3 because it is evolutionarily conserved (Supplemental Fig. 3A; “site 7” in Kwon et al. [42]), and it is the most critical site mediating the PRDM1 inhibitory effect of BCL6 in human B cells (9). We note that in the study by Kwon et al. [42], STAT3 showed only weak binding to this site in mouse CD4+ T cells, and this motif did not score functional importance in reporter assays. Reasons for the apparent discrepancy between Kwon et al.’s [42] and our results are unknown but may be related to cell type and/or species specificity. For IL-21–triggered Blimp-1 upregulation in murine lymphocytes, IRF4 appears to play a critical role. It is preloaded to many STAT3 target genes and guides STAT3 recruitment to these loci upon IL-21 stimulation and STAT3 nuclear translocation (42). IRF4 site (GAAA) occurs quite frequently in the genome. Six IRF4 sites are present in the 300-bp region surrounding the intron 3 BCL6/STAT3 site in human PRDM1. Whether any of them is occupied by IRF4 during IL-21 response or IL-21/CD40L costimulation is an issue that can be addressed in future studies.

Lastly, we have validated a robust cell line system that can be used to study the early steps in GC-to-PC phenotypic transition. All the main features we have studied, including the synergy between IL-21 and CD40L, and the importance of STAT3 and Jak3 as signal transducers of IL-21R, are consistent with prior reports in primary human B cells. A limitation of this system is that the phenotypic maturation, as least when induced by IL-21 plus CD40L, likely proceeds only to the pre-PB stage, based on the CD20/CD38 expression pattern and the amount of Abs secreted (Fig. 2). A possible explanation lies in Pax5, which should be completely turned down in mature PCs yet declined very slowly under our costimulation condition (Fig. 3). Similar results were obtained with 7A7-based system as described in the previous section. In summary, we have characterized a new cell line–based system for in vitro studies of GC-to-PC transition. Our experiments based on this system and primary tonsillar GC B cells not only highlighted a critical requirement for STAT3 at the transitional junction between activated CC and pre-PB, but also provided novel and important insights into the synergy between IL-21 and CD40L during PC differentiation.

Acknowledgments
We are grateful to Drs. Yong Sung Choi and Alexander Dent for the kind gifts of the HK cells and the Blimp-1 promoter reporter, respectively. We also thank Dr. Zhiping Li for generating the 3T3-CD40L stable cell line. Drs. Irina Velichutina and Weimin Ci for assistance with the MACS-based tonsillar GC B cell purification, Dr. Yun Mai for additional technical assistance, and Drs. Barbara Birshtein and Matthew Scharff for critical review of this manuscript.

Disclosures
The authors have no financial conflicts of interest.

References